Estia Health (ASX:EHE) share price dips on class action settlement

The Estia Health (ASX: EHE) share price dipped and then recovered today after news it has received approval to settle a class action lawsuit.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Estia Health Ltd (ASX: EHE) received Federal Court approval this afternoon to settle a class action brought against it.

The Estia Health share price dipped sharply immediately after the news was announced to the ASX, but has since returned to its prior trading level of $2.50, up 2%.

Estia Health is one of Australia's largest residential aged care providers delivering care to more than 8,000 older Australians each year.

Let's have a closer look at the settlement and class action brought against the company.

2 professionals shaking hands

Class action

The class action against Estia has been ongoing since July 2019. Filed to the Federal Court by law firm Phi Finney McDonald, it relates to alleged breaches of the company's disclosure obligations in 2015 and 2016.

The lawsuit concerned shareholders who had bought shares in the company or acquired long exposure to Estia shares by entering into equity swap confirmations between August 2016 and October 2016.

At the time, the Australian Financial Review reported the class action alleged Estia didn't disclose difficulties it was experiencing around the time it published its 2016 financial year results. It also alleged the company gave misleading guidance for the 2017 financial year. 

In February 2021, Estia advised the market it had reached an agreement to settle the class action, conditional on whether the settlement would receive Federal Court approval.

Today, Estia said that the cost of the settlement is $38.5 million, of which it has contributed $12.35 million. The remaining balance is to be paid by Estia's insurers.

Estia Health share price snapshot

The Estia Health share price has been a strong performer on the ASX lately. Currently, it's up 41% year to date and has lifted 72% over the last 12 months.

The company has a market capitalisation of around $640 million, with approximately 261 million shares outstanding.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »